Merck, Inc.
🇺🇸United States
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromesHematologic MalignanciesLeukemiaMyeloid MetaplasiaLymphoma
- Interventions
- First Posted Date
- 2004-06-28
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00086125
- Locations
- 🇺🇸
University of Chicago Hospitals, Section of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
Phase 2
Terminated
- Conditions
- Retinal Detachment
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00083967
- Locations
- 🇺🇸
Retina Assocites of Cleveland, Inc., Cleveland, Ohio, United States
🇺🇸Cleveland Clinical Foundation, Cleveland, Ohio, United States
🇺🇸Retina Vitreous Associates Medical Group, Los Angeles, California, United States
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Phase 2
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00083343
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
Phase 2
Completed
- Conditions
- AspergillosisCandidiasis
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00082524
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
Phase 2
Completed
- Conditions
- NeutropeniaFever
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00082537
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Phase 2
Terminated
- Conditions
- Primary Peritoneal Cavity CancerOvarian Cancer
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 132
- Registration Number
- NCT00003880
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: PEGASYS (peginterferon alfa-2a)Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: COPEGUS (ribavirin)
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4469
- Registration Number
- NCT00081770
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
- First Posted Date
- 2004-04-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00081510
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
Phase 3
Completed
- Conditions
- Vomiting
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00080444
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm MetastasisBrain Neoplasms
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00076856
© Copyright 2025. All Rights Reserved by MedPath